Hangzhou Sciwind Biosciences Co., a company from China, said its drug, ecnoglutide, led to more than 15% weight loss after 48 weeks when given at its highest dose, Amber Tong of Bloomberg reports. While the trial did not compare ecnoglutide to other existing drugs, the results were similar to what Eli Lilly’s (LLY) Zepbound showed in previous China studies, Bloomberg adds, citing comments made by Sciwind CEO Hai Pan in an interview. Approval for Ecnoglutide could come as soon as early 2026 and, once approved, will compete with Zepbound and Novo Nordisk’s (NVO) Wegovy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk presented results from its Phase 3b FRONTIER5 trial on Mim8
- Novo Nordisk announces REDEFINE 1 trial of CagriSema met co-primary endpoints
- Novo Nordisk price target lowered to $90 from $110 at Argus
- Eli Lilly Stock (LLY) Beefs Up as India Watches its Weight
- Eli Lilly (LLY) to Offer Higher Doses of Its Weight-Loss Drug on Website
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue